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Comparative effectiveness
research is often scarcely
available for innovative
radiation therapy techniques,
making it challenging to
examine (cost-)effectiveness.
Combining normal tissue
complication probability
models and planning studies
with data on costs and
quality of life is proposed as
feasible and informative to
bridge this gap of evidence.
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Open access undePurpose: To use Normal Tissue Complication Probability (NTCP) models and comparative
planning studies to explore the (cost-)effectiveness of swallowing sparing intensity modulated
proton radiotherapy (IMPT) compared with swallowing sparing intensity modulated radio-
therapy with photons (IMRT) in head and neck cancer (HNC).
Methods and Materials: A Markov model was constructed to examine and compare the costs
and quality-adjusted life years (QALYs) of the following strategies: (1) IMPT for all patients;
(2) IMRT for all patients; and (3) IMPT if efficient. The assumption of equal survival for IMPT
and IMRT in the base case analysis was relaxed in a sensitivity analysis.
Results: Intensity modulated proton radiation therapy and IMRT for all patients yielded 6.620
and 6.520 QALYs and cost V50,989 and V41,038, respectively. Intensity modulated proton radi-
ation therapy if efficient yielded 6.563 QALYs and cost V43,650. The incremental cost-
effectiveness ratio of IMPT if efficient versus IMRT for all patients was V60,278 per QALY
gained. In the sensitivity analysis, IMRT was more effective (0.967 QALYs) and less expensive
(V8218) and thus dominated IMPT for all patients.
Conclusions: Cost-effectiveness analysis based on normal tissue complication probability
models and planning studies proved feasible and informative and enables the analysis of indi-
vidualized strategies. The increased effectiveness of IMPT does not seem to outweigh the higher
costs for all head-and-neck cancer patients. However, when assuming equal survival among bothSc, Department of Health
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lated proton radiation
therapy is expected to be
cost-effective compared with
intensity modulated photon
radiation therapy for selected
patients.modalities, there seems to be value in identifying those patients for whom IMPT is cost-
effective.
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The costs of cancer care are expected to accelerate owing to the
aging population and costly new treatments, such as proton
radiation therapy (1, 2). Because resources are scarce, it is
important to consider the (cost-)effectiveness of new technologies
(2). Economic evaluations are often performed using decision-
analytic modeling to examine the cost-effectiveness ratio and
guide evidence-based decision making under uncertainty (3).
Economic evaluations frequently rely on comparative effective-
ness research to estimate the effectiveness, patient-reported
outcomes, and resource use. However, comparative effectiveness
research is sparsely available for proton radiation therapy (4).
Normal tissue complication probability (NTCP) models combined
with comparative planning studies might be informative to bridge
this gap of evidence. Normal tissue complication probability
models estimate the probability of toxicity according to the
expected radiation dose to healthy tissues. Comparative plan-
ning studies compare the dose distributions in patients for
different radiation therapy techniques. Hence, NTCP models
and comparative planning studies can be used in economic eval-
uations to estimate the expected benefit of innovative radiation
therapy techniques. To explore this methodology, we examine
the cost-effectiveness of intensity modulated proton radiation
therapy (IMPT) as opposed to the current standard: intensity
modulated radiation therapy with photons (IMRT) in head-and-
neck cancer (HNC).
After radiation therapy for HNC, treatment-related toxicities
like xerostomia and dysphagia substantially affect patients’
health-related quality of life (5). Planning studies suggest that
proton radiation therapy, with its favorable in-depth dose distri-
bution, has the ability to reduce the radiation dose to healthy
tissues and hence the occurrence of toxicity compared with
photons (6). However, there is no clinical evidence that supports
these theoretical benefits of protons (4, 6). Therefore, we aimed to
combine NTCP models and comparative planning data in a model-
based economic evaluation to explore the (cost-)effectiveness of
swallowing-sparing IMPT (scanned) compared with swallowing-
sparing IMRT for HNC patients. Swallowing-sparing techniques
have the ability to reduce the dose to swallowing structures with
similar dose to the parotid and submandibular glands compared
with standard techniques. Consequently, swallowing-sparing
techniques may reduce the occurrence of dysphagia and hence
limit the impact of treatment on quality of life (5, 7). These
swallowing-sparing techniques can be considered the best avail-
able IMRT and IMPT treatments. It is expected that not all HNC
patients have an equal expected benefit from IMPT. Therefore, we
will also examine an individualized strategy wherein IMPT is only
administered to patients for whom IMPT is expected to be cost-
effective.Methods and Materials
Markov model description
The study population consisted of locally advanced (stage III-IV)
HNCpatients (oral cavity, laryngeal, andpharyngeal cancer), agedon
average 61 years at start of radiation therapy and pretreatment
Radiation Therapy Oncology Group (RTOG) grade <2 dysphagia
and xerostomia. A decision-analytic Markov cohort model was
constructed to estimate the expected costs and effects of 3 treatment
strategies: (1) IMPT for all patients; (2) IMRT for all patients; and (3)
IMPT if efficient: patients for whom IMPT is expected to be cost-
effective receive IMPT, the remaining patients receive IMRT.
Our analysis focuses on the question what type of radiotherapy
should be provided if radiotherapy is the therapy of choice.
Because surgery is complementary to radiation therapy, it is not
considered as comparator.
Through transiting a hypothetical cohort of patients between
mutually exclusive health states, a Markov model aims to reflect
the course of a disease to compare outcomes for competing
interventions (3). The Markov model consisted of 7 health states
(as illustrated in Fig. 1): (a) disease free without toxicity;
(b) disease free with xerostomia RTOG grade 2; (c) disease
free with xerostomia and dysphagia RTOG grade 2; (d) disease
free with dysphagia RTOG grade 2; (e) locoregional recurrence;
(f) distant metastasis; and (g) death.
To incorporate the reversibility of acute toxicity during the
first 6 months after radiation therapy, a cycle time of 6 months
was used in the first year; afterward the cycle time was 1 year.
A lifetime time horizon was used.
Markov model assumptions
The main assumption was that disease progression (including
radiation-induced cancer) and thus survival were equal for the
comparators. This was assumed because the tumor dose in the
planning studies used to estimate toxicity was similar for both
modalities, and available clinical evidence does not show statis-
tically significant differences in survival (6). Second, toxicity
occurring in the first 6 months was (partly) acute toxicity and thus
(partly) reversible. Patients can for instance transit from disease
free with xerostomia to disease free without toxicity after the first
6 months. Thereafter, toxicity was assumed to be irreversible.
Markov model input
Transition probabilities
The occurrence of xerostomia and/or dysphagia was estimated
according to 2 available NTCPmodels (8, 9). Mean radiation dose to
(e) Loco-regional
Recurrence
(f) Distant 
metastasis
(b) Disease free 
xerostomia
grade ≥2*
(c) Disease free 
dysphagia & xerostomia
grade ≥2*
(d) Disease free 
dysphagia
grade ≥2*
(a) Disease free 
no toxicity
(g) Death (all causes mortality)
Fig. 1. Diagrammatic representation of the model structure. Toxicity that occurred in the first 6 months was (partly) reversible.
Therefore, patients are allowed to move between health states a, b, c, and d 6 months after radiation therapy. Thereafter, toxicity was
assumed to be irreversible. *Toxicity was defined according to the presence of Radiation Therapy Oncology Group grade 2 or higher.
yThere was no transition from locoregional recurrence to death via distant metastasis. This was done first because patients who develop
distant metastasis are expected to die within 1 year (Appendix 3). If we would add the transition from locoregional recurrence to death via
distant metastasis, it will last 1 year or more before patients die due to distant metastasis. Second, the intermediate step to distant metastasis
was already included in the probabilities used to calculate death after locoregional recurrence (Appendix 3).
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xerostomia RTOG grade 2 at 6 and 12 months after radiotherapy (8).
Mean dose to the pharyngeal constrictor muscle superior and the
supraglottic area predicted dysphagia RTOG grade 2 at 6 and 12
months after radiation therapy (Appendix 1, available online) (9).
The required dose parameters were retrieved from a planning study
(nZ25) comparing swallowing-sparing IMRT and swallowing-
sparing IMPT (7). Subsequently, the individual dose parameters
and NTCP models were used to calculate individual IMPT/IMRT
toxicity probabilities. These individual probabilities were averagedTable 1 Method to calculate toxicity for the IMPT if efficient strate
Patient
Probability of
xerostomia (%) ICER
IMPT IMRT IMPT vs IMRT (V
1 25.5 41.3 93,302
2 18.9 36.6 169,448
3 23.6 55.2 44,358
4 26.7 37.2 150,041
Y Y Y Y
25 25.8 45.1 89,593
Mean probability of xerostomia for the IMPT if efficient strategy
Abbreviations: ICER Z incremental cost-effectiveness ratio; IMPT Z inte
radiation therapy with photons.
* Patients will only receive IMPT in this scenario if IMPT is expected to be c
the threshold of 80,000 per QALY gained.to obtain the average probabilities. The toxicity probabilities for
IMPT if efficient were obtained by first determining which treatment
(IMPT/IMRT) was expected to be cost-effective for each individual
patient. This was done by using the individual dose parameters and
toxicity probabilities to calculate individual cost-effectiveness.
Second, in patients for whom IMPT was expected to be cost-
effective the IMPT probabilities were used, whereas the IMRT
probabilities were used in the remaining patients. Third, the obtained
individual probabilities were averaged (calculation is illustrated in
Table 1).gy: Illustrated for xerostomia 6 months after radiation therapy
Preferred Probability of xerostomia (%)
) IMPT/IMRT IMPT if efficient*
IMRT 41.3
IMRT 36.6
IMPT 23.6
IMRT 37.2
Y Y
IMRT 45.1
37.1%
nsity modulated proton radiation therapy; IMRT Z intensity modulated
ost-effective compared with IMRT (grey fields), thus if the ICER is below
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dysphagia was calculated using conditional toxicity probabilities
from a cross-sectional survey (Appendixes 1 and 2) (5).
Disease progression for all comparators was based on a
meta-analysis that compared radiation therapy with and without
chemotherapy in curatively treated nonmetastatic HNC (10).
These probabilities were extracted from the concomitant chemo-
therapy arm (current standard treatment for advanced HNC).
Age-dependent background mortality was used for disease-
free patients. An increased mortality probability was used for
patients who had locoregional recurrence or distant metastases
(Appendix 3).
Effects and costs
Quality of life in terms of utility scores was used as outcome
measure. Utility scores provide a single index value for health
status, ranging from 0 (death) to 1 (full health). Utility scores were
derived from a cross-sectional study (nZ396) using the Euroqol-
5D questionnaire in Dutch HNC patients (Appendix 3) (5). Utility
scores were combined with life expectancy to calculate quality-
adjusted life years (QALYs).
The health care perspective was used to calculate costs using
activity-based costing. Unit prices and resource use were based on
guidelines, a cross-sectional survey (5), or if necessary expert
opinion (Appendixes 4 and 5).
The primary treatment costs for IMPT were calculated by
multiplying treatment costs for IMRT with a cost ratio of 2.1
(1, 11). For IMPT if efficient, both IMPT and IMRT treatment
plans were made to compare individual dose distributions and
decide upon the most efficient treatment per patient. Therefore,
costs of an extra treatment plan (V88) were added for this strategy.
A half-cycle correction was applied for QALYs and costs (12).
Future QALYs and costs were discounted by rates of 1.5%
and 4.0%, respectively (13). All costs were converted to the 2010
price level.
Markov model analyses
Expected mean costs, occurrence of toxicity, disease- and toxicity-
free life years (DTFLYs) and QALYs were estimated for all
comparators. Subsequently, the incremental cost-effectiveness
ratio (ICER) was calculated by dividing the incremental costs
by the incremental QALYs. The ICER represents the costs of an
additional QALY gained when comparing 2 strategies. Whether
a treatment strategy is considered cost-effective depends on how
much society is willing to pay per gained QALY, which is referred
to as the ceiling ratio. We adopted a ceiling ratio of V80,000,
because this is the informal ceiling ratio for a high burden of
disease in The Netherlands.
Sensitivity analyses
The assumption of equal disease progression for IMPT and IMRT
was relaxed in a sensitivity analysis. The probabilities used in this
analysis were based on a synthesis (6) of available clinical studies
for oropharyngeal carcinomas (Appendix 3).
Probabilistic sensitivity analyses were performed to reflect the
uncertainty in the input parameters and its impact on the estimated
(cost-)effectiveness (3). This was done by assigning a distribu-
tion to the input parameters (Appendixes 1-4) and subsequently
drawing random values from these distributions using Monte
Carlo simulation (20,000 iterations). The results of theprobabilistic sensitivity analyses were presented using cost-
effectiveness acceptability curves. For different ceiling ratios
this curve shows the probability that a treatment strategy is cost-
effective (3).
Value of information analyses
Because the results are surrounded by uncertainty, chances are that
the wrong decision is being made when implementing the most
cost-effective strategy. The expected value of perfect information
(EVPI) analysis assesses the expected costs of this decision
uncertainty. Hence, the EVPI places a maximum that society
should be willing to pay for further evidence to reduce this
uncertainty (3).
The population EVPI was calculated by multiplying the EVPI
per patient by the effective population in the next 10 years
(expected life span of the technology) and discounted by a rate of
4% (13). The effective population was calculated according to
a yearly incidence of 2265 HNC patients in The Netherlands
(Dutch cancer registry 2008), of which 2063 were expected to
receive radiation therapy, minus the estimated proportions
of patients with early-stage HNC (33%) and/or pretreatment
dysphagia and/or xerostomia grade 2 (36%).
To identify the most valuable research topics, the EVPI for
(groups of) parameters was calculated for the NTCP models,
disease progression, utility scores, and costs. All analyses were
performed in Microsoft Office Excel (Microsoft, Redmond, WA).
Results
The estimated occurrence of xerostomia and dysphagia at
12 months was lowest for IMPT for all patients (22% and 18%),
followed by IMPT if efficient (36% and 21%) and IMRT for all
patients (44% and 23%) (Appendix 1).
IMPT for all patients was the most effective (6.620 QALYs,
5.800 DTFLYs) and most expensive (V50,989) strategy
(Table 2). IMRT for all patients was the least effective (6.520
QALYs, 4.197 DTFLYs) and least expensive (V41,038) strategy.
The difference in costs between these 2 strategies was mainly
due to higher primary treatment costs (V21,100 vs V10,048). For
all 25 patients, IMPT resulted in more QALYs compared with
IMRT. Restricting IMPT to the 7 patients (28%) for whom IMPT
is expected to be cost-effective (IMPT if efficient) would yield
6.563 QALYs and 4.875 DTFLYs at an estimated cost of
V43,650.
IMPT if efficient as opposed to IMRT for all patients resulted in
an ICER of V60,278 per QALY gained. IMPT for all patients
compared with IMPT if efficient resulted in an ICER of V127,946
per QALY gained. IMPT if efficient can thus be regarded as the
most cost-effective strategy (Table 2).
IMPT if efficient had the highest probability (62%) of being the
most cost-effective strategy (Fig. 2). The value of further research
was estimated to be V2.4 million for the total population.
Further research focusing on utility scores after xerostomia
(V0.7 million), NTCP models for dysphagia (V0.3 million), and
for xerostomia (V0.1 million) is most worthwhile.
In the sensitivity analysis, IMRT for all patients yielded 1.493
more QALYs and was V8093 less expensive and thus dominated
IMPT for all patients (Table 3). This was the case for all indi-
vidual patients. The individualized strategy was thus equal to
IMRT for all patients plus the costs of an extra treatment plan and
is therefore not considered in the sensitivity analysis.
Table 2 Base case results of the cost-effectiveness analyses (sorted by QALY)
Treatment
strategy
Expected outcomes (95% CI*)
Comparator
Increments (95% CI*) ICER
QALY/DTFLYy Costs (V)
Incremental
QALY/DTFLYy
Incremental
costs (V)
V per QALY/
DTFLYy
IMRT for all
patients
6.520 (5.781 to
7.018)
41,038 (38,878 to
44,158)
IMPT if efficient 6.563 (5.818 to
7.059)
43,650 (41,523 to
46,949)
IMRT for all
patients
0.043 (0.014 to 0.073) 2612 (2008 to 3306) 60,278
IMPT for all
patients
6.620 (5.869 to
7.115)
50,989 (48,227 to
54,852)
IMPT if
efficient
0.057 (0.016 to 0.102) 7339 (6001 to 8744) 127,946
IMRT for all
patients
4.197 (3.198 to
4.964)
41,038 (38,878 to
44,158)
IMPT if efficient 4.875 (3.761 to
5.630)
43,650 (41,523 to
46,949)
IMRT for all
patients
0.678 (0.448 to 0.854) 2612 (2008 to 3306) 3854
IMPT for all
patients
5.800 (4.536 to
6.594)
50,989 (48,227 to
54,852)
IMPT if
efficient
0.925 (0.628 to 1.182) 7339 (6001 to 8744) 7936
Abbreviations: CIZ confidence interval; DTFLYZ disease and toxicity free life year; QALYZ quality-adjusted life year. Other abbreviations as in
Table 1.
* Confidence interval is based on probabilistic analysis.
y Values in lower 3 rows represent DTFLY.
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being cost-effective (Fig. 2).
Discussion
The original aspect of this assessment was that despite the lack of
comparative effectiveness research, we were able to explore the
cost-effectiveness of IMPT versus IMRT. The present study
showed that using NTCP models combined with comparative
planning studies into model-based economic evaluations is
feasible and informative. Besides examining the (cost-)effective-
ness, this methodology can potentially be used to identify patients
for whom particular treatments are more or less (cost-)effective
than for the whole group. If equal disease control is assumed,
IMPT is more effective than IMRT for all HNC patients. Thus, on
the basis of effectiveness, IMPT would be the treatment of choice
for all patients. However, the increased effectiveness of IMPT
does not outweigh its additional costs for all patients. Adminis-
tering IMPT only to selected patients for whom it is expected to be
cost-effective (IMPT if efficient) seems the most cost-effective
treatment strategy. IMRT is the dominant strategy if disease
progression is based on clinical evidence. The quality and quantity
of available studies is, however, poor (6). Accordingly, it is
possible that differences in disease progression found in these
studies and thus the dominance of IMRT are not a reflection of
actual differences.
Some limitations should also be discussed. First, the presented
methodology is not yet validated. As with any novel methodology,
further research and application of the methodology in practice are
needed to demonstrate its validity. Second, disease progression
was based on a meta-analysis that included trials conducted before
2000. Because recent studies show more favorable results (10),
disease progression might have been overestimated. Third, the
health care perspective was used for cost calculation. The societal
perspective, including productivity losses, might favor IMPT
because less toxicity presumably reduces productivity losses. The
preceding 2 limitations can be regarded as conservative towardIMPT. Fourth, radiation-induced cancer was not incorporated,
because evidence on the magnitude and direction of this effect is
lacking (14). Additionally, given that radiation-induced cancer
generally occurs years after radiation therapy, it is probably not an
influential factor in this older population. Fifth, utility scores for
the different health states were retrieved from a cross-sectional
study (5). Preferably, these utility scores are based on a prospec-
tive study to correct for possible baseline differences. However,
the occurrence of xerostomia and/or dysphagia is expectedly
independent of baseline utility scores. Sixth, 2 available prediction
models (8, 9) were used to predict the occurrence of toxicity. As
with all prediction models, these models can possibly be opti-
mized to achieve more accurate predictions. For the validity of the
proposed methodology, it is of great importance to use valid
prediction models. This uncertainty is incorporated in the proba-
bilistic sensitivity analysis. Seventh, the analyses were based on
swallowing-sparing radiation therapy techniques. Choice of these
techniques most likely decreases the QALY gain for IMPT
compared with IMRT owing to a smaller reduction of dysphagia
(7). Hence, using swallowing-sparing techniques can be regarded
as conservative toward IMPT. Those interested can use the inter-
active decision support tool (www.predictcancer.org) to examine
the cost-effectiveness of IMPT versus IMRT for any other radia-
tion therapy technique. Eighth, incorporating additional time
points to estimate toxicity would lead to a more realistic repre-
sentation of clinical practice. However, because this concerns both
comparators, the impact on the difference in toxicity and conse-
quently the difference in QALYs is probably small. Finally, to
estimate the occurrence of toxicity, we used NTCP models vali-
dated with photons. It has been argued that using these NTCP
models for protons possibly requires modification because
photons and protons differ in low to intermediate dose distribu-
tions (15). At this moment, it is unknown to what degree NTCP
models validated in photon studies can be used for protons.
One previous study (16) addressed the cost-effectiveness of
proton radiation therapy in HNC and reported a substantially
lower ICER of V3811 per QALY for proton versus photon radi-
ation therapy than the present study. This discrepancy can be
Fig. 2. Cost-effectiveness acceptability. The vertical line represents the ceiling ratio that was adopted in our analyses (V80,000 per
quality-adjusted life year gained). IMPT Z intensity modulated proton radiation therapy; IMRT Z intensity modulated radiation therapy
with photons.
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equal survival for both comparators, whereas Lundkvist et al (16)
assumed a mortality risk reduction of 24% for proton radiation
therapy.
To our knowledge, no other studies used NTCP models in
economic evaluations. Konski et al (17) used dose-response dataTable 3 Sensitivity analysis (sorted by QALY)
Treatment
strategy
Expected outcomes (95% CI*)
ComparatorQALY/DTFLYy Costs (V)
IMPT for all
patients
6344 (3.729 to
10.581)
48,042 (44,372 to
54,416)
IMRT for all
patients
7.937 (6.309 to
9.741)
39,949 (36,445 to
45,273)
IMPT for al
patients
IMPT for all
patients
5.425 (2.677 to
9.917)
48,042 (44,372 to
54,416)
IMRT for all
patients
5.114 (3.608 to
6.774)
39,949 (36,445 to
45,273)
IMPT for al
patients
Abbreviations: As in Tables 1 and 2.
* Confidence interval is based on probabilistic analysis.
y Lower two rows represent DTFLY.to predict recurrences in an economic evaluation for proton radi-
ation therapy in prostate cancer.
The main research implication is that the applied study
method, possibly combined with dose-response data for disease
progression (17), is feasible and informative to explore the
potential (cost-)effectiveness of innovative radiation therapyIncrements (95% CI*) ICER
Incremental
QALY/DTFLYy
Incremental
costs (V)
V per QALY/
DTFLYy
l 1.493 (2.953 to
4.786)
8093 (13,546 to
3478)
Dominant
l 0.310 (4.943 to
2.792)
8093 (13,546 to
3478)
26,094
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especially comparative evidence is obviously superior to the
proposed methodology. However, the proposed methodology
offers a solution if clinical data are lacking and it is not desirable
to wait or postpone decisions until clinical data become available.
For proton radiation therapy this methodology may provide new
insights to the debate considering pros and cons of clinical trials
comparing proton and photon radiation therapy (4). It would be
interesting for this debate to explore which radiation therapy
technique is optimal and consider planning studies primarily
focused on sparing other structures than the swallowing structures.
Additionally, further research on utility scores after xerostomia
and NTCP models seems most valuable to reduce decision
uncertainty.
Our results showed that, on the basis of equal survival
for IMPT and IMRT, IMPT is cost-effective for individually
selected patients in The Netherlands. For clinical practice it is
therefore recommended to make a trade-off between expected
costs and benefits for each individual patient. The presented
methodology can be used to make this individual trade-off. This
is in line with recent policy recommendations (18). In these
recommendations it is mentioned that a clinically significant
reduction of complications is required for patients to be eligible
for IMPT. However, it is not specified what can be considered as
a clinically significant reduction. It is required to specify
a threshold when patients are eligible for IMPT, either based on
cost-effectiveness or solely on effectiveness. In our analyses, the
reduction in complications was expressed in terms of QALYs. The
adopted ceiling ratio of V80,000 per QALY gained enabled us
to calculate which treatment is preferred according to cost-
effectiveness.
In deciding which patients receive IMPT, the proposed
methodology, if validated by clinical data, could act as a clinical
decision support tool. Our tool is published online as example
(www.predictcancer.org). Treatment allocation could then be
based on individual patient data to ensure that IMPT is assigned to
patients for whom it is expected to be worthwhile.References
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